Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01187901 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
A Phase 2 study of Adenomatous Polyposis Coli, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT01187901 is a Phase 2 study of Adenomatous Polyposis Coli that has completed, run by University of Utah. The registered enrollment target is 92 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01187901, a Phase 2 study of Adenomatous Polyposis Coli, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine in a randomized, placebo-controlled, phase II trial if the combination of sulindac and erlotinib causes a significant regression of duodenal and colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) patients.
Conditions Studied
Interventions
- DRUG Erlotinib
- DRUG Sulindac
- DRUG Placebo A
- DRUG Placebo B
Study Locations (1)
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01187901
The ClinicalTrials.gov registry entry for NCT01187901 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adenomatous Polyposis Coli appearing as the primary indexed condition, and to 4 interventions - of which Erlotinib is the first listed.
NCT01187901 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT01187901 about?
NCT01187901 is a clinical study titled "A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients". The purpose of this study is to determine in a randomized, placebo-controlled, phase II trial if the combination of sulindac and erlotinib causes a significant regression of duodenal and colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) patients.
What is the current status of trial NCT01187901?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2010-04. Estimated completion is 2014-07.
What conditions does trial NCT01187901 study?
This clinical trial studies the following conditions: Adenomatous Polyposis Coli.
What interventions are being tested in trial NCT01187901?
The interventions under investigation include: Erlotinib (DRUG), Sulindac (DRUG), Placebo A (DRUG), Placebo B (DRUG).
Who is sponsoring clinical trial NCT01187901?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01187901 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenomatous Polyposis Coli
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.